119 related articles for article (PubMed ID: 37852159)
41. Lipid lowering targets are easier to attain than those for treatment of hypertension in type 2 diabetes.
Sherlock M; Mylotte D; Mac Mahon J; Moore KB; Thompson CJ
Ir J Med Sci; 2006; 175(4):36-41. PubMed ID: 17312827
[TBL] [Abstract][Full Text] [Related]
42. A post hoc analysis of saxagliptin efficacy and safety in patients with type 2 diabetes stratified by UKPDS 10-year cardiovascular risk score.
Bonora E; Bryzinski B; Hirshberg B; Cook W
Nutr Metab Cardiovasc Dis; 2016 May; 26(5):374-9. PubMed ID: 27033025
[TBL] [Abstract][Full Text] [Related]
43. Cardiovascular risk factors are not treated to target in hypertensive patients in primary care.
Nieburg I; Kahan T
Blood Press; 2010 Jun; 19(3):176-81. PubMed ID: 20429693
[TBL] [Abstract][Full Text] [Related]
44. The effect of interventions to prevent cardiovascular disease in patients with type 2 diabetes mellitus.
Huang ES; Meigs JB; Singer DE
Am J Med; 2001 Dec; 111(8):633-42. PubMed ID: 11755507
[TBL] [Abstract][Full Text] [Related]
45. Management of type 2 diabetes mellitus and cardiovascular risk: lessons from intervention trials.
Yki-Järvinen H
Drugs; 2000 Nov; 60(5):975-83. PubMed ID: 11129129
[TBL] [Abstract][Full Text] [Related]
46. Effects of blood-pressure-lowering treatment on outcome incidence in hypertension: 10 - Should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of randomized trials.
Thomopoulos C; Parati G; Zanchetti A
J Hypertens; 2017 May; 35(5):922-944. PubMed ID: 28141660
[TBL] [Abstract][Full Text] [Related]
47. Comparison of probability of stroke between the Copenhagen City Heart Study and the Framingham Study.
Truelsen T; Lindenstrøm E; Boysen G
Stroke; 1994 Apr; 25(4):802-7. PubMed ID: 8160224
[TBL] [Abstract][Full Text] [Related]
48. The Microalbuminuria Education Medication and Optimisation (MEMO) study: 4 years follow-up of multifactorial intervention in high-risk individuals with type 2 diabetes.
Crasto W; Morrison AE; Gray LJ; John E; Jarvis J; Brela J; Khunti K; Troughton J; Lawrence IG; McNally PG; Davies MJ
Diabet Med; 2020 Feb; 37(2):286-297. PubMed ID: 31505051
[TBL] [Abstract][Full Text] [Related]
49. Systematic review on urine albumin testing for early detection of diabetic complications.
Newman DJ; Mattock MB; Dawnay AB; Kerry S; McGuire A; Yaqoob M; Hitman GA; Hawke C
Health Technol Assess; 2005 Aug; 9(30):iii-vi, xiii-163. PubMed ID: 16095545
[TBL] [Abstract][Full Text] [Related]
50. ESH-ESC guidelines for the management of hypertension.
Erdine S; Ari O; Zanchetti A; Cifkova R; Fagard R; Kjeldsen S; Mancia G; Poulter N; Rahn KH; Rodicio JL; Ruilope LM; Staessen J; van Zwieten P; Waeber B; Williams B
Herz; 2006 Jun; 31(4):331-8. PubMed ID: 16810473
[TBL] [Abstract][Full Text] [Related]
51. Adverse prognostic significance of new diabetes in treated hypertensive subjects.
Verdecchia P; Reboldi G; Angeli F; Borgioni C; Gattobigio R; Filippucci L; Norgiolini S; Bracco C; Porcellati C
Hypertension; 2004 May; 43(5):963-9. PubMed ID: 15037557
[TBL] [Abstract][Full Text] [Related]
52. Class of antihypertensive drugs, blood pressure status, and risk of cardiovascular disease in hypertensive patients: a case-control study in Japan.
Kono S; Kushiro T; Hirata Y; Hamada C; Takahashi A; Yoshida Y
Hypertens Res; 2005 Oct; 28(10):811-7. PubMed ID: 16471175
[TBL] [Abstract][Full Text] [Related]
53. Antihypertensive treatment of patients with diabetes and hypertension.
Julius S; Majahalme S; Palatini P
Am J Hypertens; 2001 Nov; 14(11 Pt 2):310S-316S. PubMed ID: 11721889
[TBL] [Abstract][Full Text] [Related]
54. Impact of a multifactorial treatment programme on clinical outcomes and cardiovascular risk estimates: a retrospective cohort study from a specialised diabetes centre in Denmark.
Safai N; Carstensen B; Vestergaard H; Ridderstråle M
BMJ Open; 2018 Mar; 8(3):e019214. PubMed ID: 29550776
[TBL] [Abstract][Full Text] [Related]
55. Absolute cardiovascular risk scores and medication use in rural India: a cross-sectional study.
Birhanu MM; Evans RG; Zengin A; Riddell M; Kalyanram K; Kartik K; Suresh O; Thomas NJ; Srikanth VK; Thrift AG
BMJ Open; 2022 Apr; 12(4):e054617. PubMed ID: 35459666
[TBL] [Abstract][Full Text] [Related]
56. Impact of metabolic surgery on 10-year cardiovascular disease risk in Chinese individuals with type 2 diabetes.
Ke Z; Li F; Zhou X; Sun F; Zhu Z; Tong W
Surg Obes Relat Dis; 2021 Mar; 17(3):498-507. PubMed ID: 33358863
[TBL] [Abstract][Full Text] [Related]
57. The significance of plasma adrenomedullin and calcitonin gene-related peptide concentration in patients with Type 2 diabetes mellitus who are treated for cardiovascular risk factors.
Charvat J; Svab P; Havlin J; Bilek R; Zamrazil V
Neuro Endocrinol Lett; 2014; 35(2):154-8. PubMed ID: 24878981
[TBL] [Abstract][Full Text] [Related]
58. Assessment and management of hypertension in patients with type 2 diabetes.
Thomas MC; Atkins R
Intern Med J; 2009 Mar; 39(3):143-9. PubMed ID: 18771428
[TBL] [Abstract][Full Text] [Related]
59. Comparative effect of antihypertensive therapy on blood glucose level in hypertensive patients in an Indian population.
Ahmad MA; Kapur P; Khanam R; Akhtar M; Khan GH; Anwar MJ; Vohora D
Drug Res (Stuttg); 2014 May; 64(5):276-80. PubMed ID: 24132701
[TBL] [Abstract][Full Text] [Related]
60. An analysis of calibration and discrimination among multiple cardiovascular risk scores in a modern multiethnic cohort.
DeFilippis AP; Young R; Carrubba CJ; McEvoy JW; Budoff MJ; Blumenthal RS; Kronmal RA; McClelland RL; Nasir K; Blaha MJ
Ann Intern Med; 2015 Feb; 162(4):266-75. PubMed ID: 25686167
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
